Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Antiviral entities : Gilead sciences, inc. save search
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.07%
H: 0.53%
C: -0.75%
antiviral pipeline research
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities
Published: 2023-09-09 (Crawled : 04:20) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
report antiviral therapeutics market
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
Published: 2023-02-14 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.11%
H: 0.02%
C: -2.18%
antiviral impact potential innovation
The Global Antiviral Drugs Market to Exhibit Growth at a Paltry CAGR of ~4% by 2027 | DelveInsight
Published: 2023-02-02 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.16%
H: 0.08%
C: -0.41%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.87%
H: 0.01%
C: -0.55%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.16%
H: 1.98%
C: 1.56%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -1.28%
H: 3.64%
C: 3.48%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -0.75%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.62%
H: 2.22%
C: 1.94%
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 0.85%
H: 5.08%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -1.95%
H: 0.16%
C: -1.18%
global antiviral growth market
Global Antiviral Therapeutics Market 2022 to 2027 - Rising Prevalence of Viral Diseases like HIV and Hepatitis Drives Growth
Published: 2023-01-16 (Crawled : 20:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -2.74%
H: 0.43%
C: -0.99%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.33%
H: 0.33%
C: -0.94%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.83%
H: 0.52%
C: -1.09%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.01%
H: 0.69%
C: -0.1%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.1%
H: 0.22%
C: 0.02%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.26%
H: 0.37%
C: -0.74%
COCP | $1.562 -1.39% 3.9K
|
Health Technology
|
| O: 0.47%
H: 11.16%
C: 7.91%
hepatitis global antiviral hiv therapeutics growth market
Antiviral Drugs Market Size To Reach USD 50.02 BN In 2030 Due to Development Of New, Improved, And More Advanced Formulations, Such As Repurposed Drugs And Drug Combination Therapies, Says Reports and Data
Published: 2022-04-13 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.02%
H: 0.8%
C: 0.71%
drug antiviral repurposed market
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published: 2022-03-15 (Crawled : 16:00) - prnewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.47%
H: 0.62%
C: -0.18%
covid-19 viral drug treatment drug covid therapy antiviral
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
Published: 2022-02-08 (Crawled : 17:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.27%
H: 0.81%
C: -0.2%
research test antiviral
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
Published: 2021-11-22 (Crawled : 23:00) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 15.69%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.14%
H: 1.43%
C: 1.09%
antiviral tnx-3500 sars-cov-2
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
Published: 2021-09-20 (Crawled : 13:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: 0.04%
disease infectious disease test antiviral research
$76.28 Billion Anti-Viral Therapies Market, 2027 - Growing Emphasis on Launching Anti-Viral Agents
Published: 2021-03-16 (Crawled : 11:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.76%
C: 0.57%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.08%
H: 1.42%
C: 1.23%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.08%
H: 1.3%
C: 0.91%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.28%
H: 1.03%
C: 0.81%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.27%
H: 1.52%
C: 1.22%
growing therapy antiviral
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
Published: 2020-12-07 (Crawled : 12:00) - globenewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.17%
H: 0.06%
C: -1.35%
MTNB | $0.1818 0.17% 0.0% 520K
|
Health Technology
|
| O: 10.09%
H: 4.17%
C: -7.5%
biopharma collaboration disease announces collaboration liver infectious disease antiviral
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.